Early detection of Alzheimer’s disease-related changes in Parkinson’s disease and dementia with Lewy bodies could be made possible by monitoring the amyloid-β (Aβ) and phosphorylated tau (p-tau) proteins. Researchers at Nagoya University in Japan also discovered the blood levels of neurofilament light chain (NfL) protein is elevated at an early stage of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). This discovery may provide a method to identify potential patients and to make early interventions. The findings were published in npj Parkinson’s Disease.

The two forms of Lewy body disease are PD and DLB. Recent discoveries indicate that patients with these diseases share characteristics with Alzheimer’s disease, including the presence of Aβ and p-tau proteins in the brain.

Recently, researchers have directed their attention toward the early stage of these diseases, called the prodromal stage. During the prodromal stage, abnormal protein buildup begins, leading to the eventual development of the disease about 10-20 years after the onset of motor and cognitive symptoms.

A research group led by Professor Masahisa Katsuno and Dr. Keita Hiraga from Nagoya University Graduate School of Medicine measured plasma biomarkers for Alzheimer’s disease (Aβ and p-tau) and neurodegeneration (NfL) in patients with PD and DLB, as well as high-risk individuals in the prodromal stage. The study was a collaboration with the National Center for Geriatrics and Gerontology and National Institutes for Quantum Science and Technology.

Changes in the expression of proteins Aβ and p-tau were observed in patients with PD dementia (PDD) and DLB, but not in those in the prodromal stage. On the other hand, both individuals in the prodromal stage and those suffering from the diseases exhibited elevated levels of NfL.

“These findings suggest that the proteins associated with comorbid Alzheimer’s disease pathology in PDD and DLB are not present in the prodromal phase, but instead develop after the onset of the disease,” Hiraga said. “On the other hand, neuronal damage caused by α-synuclein-induced neurodegeneration leads to the release of NfL in PD and DLB. Therefore, the elevation of NfL in high-risk individuals, despite the absence of increased Alzheimer’s disease-related biomarkers, suggests that NfL may be used to detect α-synuclein-induced neurodegeneration, a key marker of disease, in the prodromal phase.”

“In PD and DLB patients, Aβ and p-tau are not present in the prodromal stage before onset but rather appear after the disease has manifested,” Katsuno added. “This chronological pattern is quite different from Alzheimer’s disease, in which Aβ and p-tau start to deposit a few decades before the onset of dementia.”

The team’s findings indicate that anti-Aβ antibody treatments for early-stage Alzheimer’s disease could be effective in treating Lewy body diseases. “Our findings suggest that Aβ accumulation in PD and DLB may occur after disease onset,” Hiraga said. “Recently, lecanemab, an anti-Aβ antibody drug, was approved for early-stage Alzheimer’s disease. This drug could also be effective against Alzheimer’s pathology in PD and DLB.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is 4 multiplied by 8?

Explore More

Antidepressant shows promise for treating brain tumors

Glioblastoma is a particularly aggressive brain tumour that at present is incurable. Cancer doctors can extend patients’ life expectancy through operations, radiation, chemotherapy or surgical interventions. Nevertheless, half of patients

New immune cell therapy benefits laboratory models of ALS and has some positive results in an individual with the disease

Immune system dysregulation and elevated inflammation contribute to the development of the fatal neurodegenerative condition amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. In new research published in

Stem cell transplants may delay disability longer than some MS medications

In people with active secondary progressive multiple sclerosis (MS), hematopoietic stem cell transplants may delay disability longer than some other MS medications, according to a study published in the December